Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today outlined its fourth-quarter 2025 priorities and provided an update on its strategic business development and acquisitio ...